MK-0482
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2.3M | 127 | 0 |
| 2019 | $383,558 | 55 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.7M | 182 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-0482 as monotherapy and in combination with pembrolizumab in participants with advanced,metastatic solid tumors. | Merck Sharp & Dohme Corporation | $2.7M | 0 |
Top Doctors Receiving Payments for MK-0482
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Hackensack, NJ | $2.7M | 182 |
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $2.7M
- Total Doctors 0
- Transactions 182
About MK-0482
MK-0482 is a biological associated with $2.7M in payments to 0 healthcare providers, recorded across 182 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2020. In 2020, $2.3M was paid across 127 transactions to 0 doctors.
The most common payment nature for MK-0482 is "Unspecified" ($2.7M, 100.0% of total).
MK-0482 is associated with 1 research study, including "A Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-0482 as monotherapy and in combination with pembrolizumab in participants with advanced,metastatic solid tumors." ($2.7M).